‘Thrilling’: Regimen reduces metastasis, recurrence in high-risk prostate cancer

CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk prostate cancer, according to findings presented in ASCO Annual Meeting’s plenary session.Men who received apalutamide (Erleada, Johnson & Johnson) and ADT in the neoadjuvant and adjuvant settings survived longer without recurrence or